CBC with differential, CD4 count, HIV RNA plasma levels, serum transaminases, fasting lipid panel; serum creatine kinase, serum amylase (as clinically indicated); HLA-B*5701 genotype status prior to initiation of therapy and prior to reinitiation of therapy in patients of unknown HLA-B*5701 status; signs and symptoms of hypersensitivity.
Advanced Practitioners Physical Assessment/Monitoring
Assess closely for any previous exposure/allergy to abacavir and evaluate risk factors for heart disease prior to beginning treatment. Patient must be closely monitored for any sign of hypersensitivity reaction, which can occur within hours or at any time and may be fatal (can also occur at reintroduction with patients who have no history of previous reaction). Assess decrease in infections and progression of disease, viral load, and CD4 count.
